4D Pharma

38 articles with 4D Pharma

• Final Results for the year ended 31 December 2020

  4/1/2021

  4D pharma plc (AIM: DDDD, NASDAQ: LBPS) (“4D”, the “Company” or, together with its subsidiaries, the “Group”), a pharmaceutical company leading the development of Live Biotherapeutics, is pleased to announce the final results for the Group for the year ended 31 December 2020.

• Completion of Merger With Longevity Acquisition Corporation and Admission of American Depositary Shares to Trading on NASDAQ

  3/22/2021

  4D pharma plc, a pharmaceutical company leading the development of Live Biotherapeutic products, a novel class of drug derived from the microbiome, is pleased to announce that its business combination with Longevity Acquisition Corporation, details of which were announced on 22 October 2020, has now become effective.

• 4D pharma Announces Completion of Merger With Longevity Acquisition Corporation

  3/22/2021

  4D pharma plc, a pharmaceutical company leading the development of Live Biotherapeutic products - a novel class of drug derived from the microbiome - announced completion of its merger with Longevity Acquisition Corporation.

• 4D Pharma Announces Private Placement

  3/17/2021

  Company expects to complete merger with Longevity Acquisition Corporation and its American Depositary Shares to be admitted to trading on NASDAQ on 22 March 2021

• 4D Pharma to Present at Upcoming Investor Conferences in March

  3/3/2021

  4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announced that 4D management will present at three upcoming investor conferences:

•  4D Pharma Appointments Paul Maier to the Board as Non-Executive Director

  3/1/2021

  4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of Paul Maier as Non-Executive Director of the Board. Mr Maier will also be a member of 4D's Audit and Risk Committee and will serve as the Company’s “audit committee financial expert"

• 4D Pharma Appoints John Beck as Chief Financial Officer and Member of the Management Team

  3/1/2021

  4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of John Beck as Chief Financial Officer (CFO) and member of the Company’s management team

• 4D Pharma Announces U.S. SEC Declares Registration Statement Effective with Respect to the Issuance of 4D Pharma American Depositary Shares on NASDAQ

  2/26/2021

  4D pharma to list ADSs on NASDAQ in conjunction with the merger agreement between 4D pharma and Longevity Acquisition Corp., a SPAC

• 4D Pharma to Participate in Upcoming Cantor Fitzgerald Microbiome Leaders Panel

  2/16/2021

  4D pharma plc, a pharmaceutical company leading the development of Live Biotherapeutic products - a novel class of drug derived from the microbiome, announces Duncan Peyton, Chief Executive Officer of 4D pharma, will participate in Cantor Fitzgerald’s virtual panel, titled “Microbiome Players with Guided Readouts in 2021,” on Thursday, February 18, 2021 at 15:00 GMT.

• 4D pharma Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate MRx0518 in Combination with BAVENCIO® for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

  2/8/2021

  4D pharma Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate MRx0518 in Combination with BAVENCIO ® for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

• Longevity Acquisition Corporation Announces 4D pharma Update on Oncology Program

  2/3/2021

  Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that on February 3, 2021 , 4D pharma plc (AIM: DDDD) ("4D pharma"), a pharmaceutical company leading the development of Live Biotherapeutic products ("LBPs") has announced progress on activities in its development program

• 4D Pharma Presents Update on Oncology Program

  2/3/2021

  Enrollment progressing well for both expanded Part B of MRx0518 and Keytruda® combination study, and pancreatic cancer study Further analysis of biomarker data in ongoing MRx0518 neoadjuvant monotherapy study

• 4D pharma to Participate in 5th Microbiome Movement Drug Development Summit Europe

  1/21/2021

  4D pharma to Participate in 5 th Microbiome Movement Drug Development Summit Europe

• Longevity Acquisition Corporation Announces 4D pharma Joining Landmark Parkinson's Progression Markers Initiative

  12/21/2020

  Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that on December 18, 2020 , 4D pharma plc (AIM: DDDD) ("4D pharma"), a pharmaceutical company leading the development of Live Biotherapeutic products ("LBPs") - a novel class of drug derived from the

• 4D pharma plc Files SEC Forms in Process to Gain NASDAQ Listing Following Merger with Longevity, a Special Purpose Acquisition Company (SPAC)

  11/27/2020

  Merger completion and NASDAQ listing expected in Q1 2021 US listing will support and accelerate ongoing development of 4D pharma’s Live Biotherapeutics

• 4D Pharma Presents New Data from Two MRx0518 Clinical Trials at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

  11/9/2020

  MRx0518 demonstrates upregulation of key immune biomarkers associated with anti-cancer activity in neoadjuvant monotherapy setting Addition of new tumor type cohorts to ongoing Part B of Phase I/II combination trial with pembrolizumab, following 42% disease control rate (DCR) in completed Part A Company to host virtual KOL event to review data on Wednesday, November 11, 2020 at 1:00pm GMT (8:00am ET)

• 4D Pharma to Host Virtual KOL Event Reviewing New Data Presented at the Society for Immunotherapy of Cancer Annual Meeting 2020 from Live Biotherapeutic MRx0518 Clinical Programs

  11/5/2020

  4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces that it will host a virtual Key Opinion Leader (KOL) event to review data presented from two ongoing clinical trials of MRx0518, the Company’s lead immuno-oncology single strain Live Biotherapeutic, as both a neoadjuvant monotherapy and combi

• Longevity Acquisition Corporation Announces Signing of Definitive Merger Agreement

  10/22/2020

  Longevity Acquisition Corporation, a publicly-traded special purpose acquisition company, announced that it has signed a definitive merger agreement with 4D pharma PLC.

• 4D Pharma Presents Additional Interim Clinical Data From Combination Study for Lead Oncology Candidate

  3/17/2020

  First global clinical confirmation of a live biotherapeutic product initiating a response in cancer patients

• Clinical Update - 4D Announce New Study of MRx0518 in Pancreatic Cancer

  1/6/2020

  4D Pharma Announces Opening of a Study Investigating MRx0518 in Combination with Radiotherapy in Patients with Resectable Pancreatic Cancer